Category: Thoratec Corp.Syndicate content

Covidien names Bill Burke as CFO to lead Medtronic merger | The week in medtech M&A

July 9, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Covidien taps integration chief to navigate Medtronic merger; Zimmer, Biomet appoint integration team; Thoratec inks $75M deal for Apica Cardiovascular; FTC wants more from Zimmer, Biomet on merger; Johnson & Johnson closes Ortho-Clinical Diagnostics sale

Covidien taps integration chief to navigate Medtronic merger

July 3, 2014 by Arezu Sarvestani

Covidien taps integration chief to navigate Medtronic merger

Thoratec inks $75M deal for Apica Cardiovascular

July 3, 2014 by Brad Perriello

Thoratec pays $35 million up front and puts another $40 million up in milestone payments for Apica Cardiovascular and its transapical access technology.

Thoratec inks $75M deal for Apica Cardiovascular

Thoratec (NSDQ:THOR) said it paid $35 million up front and agreed to another $40 million in potential milestone payments for Apica Cardiovascular and its transapical access technology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec launches HeartMate III trial

June 27, 2014 by Brad Perriello

Thoratec says it's launched a clinical trial for its HeartMate III implantable heart pump it plans to useto back a bid for CE Mark approval in the European Union.

Thoratec launches HeartMate III trial

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec: NEJM article cost us market share

May 7, 2014 by Brad Perriello

A New England Journal of Medicine report on higher-than-expected blood clot rates for Thoratec's HeartMate II implantable heart pump took market share during the 1st quarter, company officials said today.

Thoratec: NEJM article cost us market share

A New England Journal of Medicine report last year detailing sharp increases in the rate of blood clots helped take market share away from Thoratec (NSDQ:THOR) and its HeartMate II implantable heart pump, company officials said yesterday.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ReliantHeart goes head-to-head with Thoratec to aim for U.S. LVAD market

April 7, 2014 by Arezu Sarvestani

ReliantHeart touts study data finding that its HeartAssist5 left ventricular assist device poses a lower risk of blood clots and damage compared with Thoratec's HeartMate II.

ReliantHeart aims for U.S. LVAD market, goes head-to-head with Thoratec

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec recall gets FDA's highest-risk label following injuries, deaths | MassDevice.com On Call

April 3, 2014 by Arezu Sarvestani

FDA regulators put their highest-risk Class I label on a recall of Thoratec's HeartMate II implantable heart pump after 5 patients injuries and 4 deaths were reportedly associated with a defect in controlling the implants.

MassDevice.com On Call

MASSDEVICE ON CALL — The FDA issued it's highest-risk Class I warning after Thoratec (NSDQ:THOR) recalled its HeartMate II implantable heart pumps over a controller issue that the FDA said was associated 4 patient deaths and 5 serious injuries.

Thoratec updates HeartMate II controller warning

March 18, 2014 by Brad Perriello

Thoratec updates its warning about the risk of switching controllers for its HeartMate II implantable heart pump.

Thoratec updates on HeartMate II controller warning

Thoratec (NSDQ:THOR) issued an update about a problem with its HeartMate II left ventricular assist device involved in 8 serious injuries or deaths.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp